- The global launch of Bylvay was more successful than expected and Albireo doubled its net sales guidance for 2021.
- Beyond Odevixibat, Albireo was able to discover new drugs with blockbuster.
- Both early clinical assets address a market with a high medical need and have blockbuster potential with their game changing mode of action.
- Albireo's ability to tailor new drugs to attractive indications based on their expertise may make Albireo a relevant liver disease player.
For further details see:
Adult Liver Diseases: The R&D Engine Drives Albireo's Long-Term Prospects.